EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults

Sophia Zoungas, Rory Wolfe, Chris Moran, Stephen J Nicholls, Geoffrey C Cloud, Christopher M Reid, Andrew M Τonkin, Lawrence Beilin, Anthony S Wierzbicki, Trevor T-J Chong, Jonathan C Broder, Andrea J Curtis und 7 weitere

New England Journal of Medicine · 01.10.2026 · 395 (13) · 1259-1272

DOI: 10.1056/nejmoa2607314 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 01.10.2026. Verfasst von Sophia Zoungas und 18 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Atorvastatin, Cardiovascular Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Disability Evaluation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Heart Foundation of Australia, National Health and Medical Research Council, Faculty of Medicine, Nursing and Health Sciences, Monash University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The effectiveness and safety of statins for the primary prevention of cardiovascular events and the extension of disability-free survival among older adults remain uncertain. METHODS: We conducted a double-blind, randomized, placebo-controlled trial at general medical practices across Australia. Community-dwelling adults at least 70 years of age with no history of cardiovascular disease, diabetes, or dementia were randomly assigned in a 1:1 ratio to receive atorvastatin at a dose of 40 mg once daily or identical placebo. The two primary end points were a composite of death from cardiovascular causes, nonfatal myocardial infarction or stroke, or coronary revascularization (to assess effects on major cardiovascular events) and a composite of death from any cause, dementia, or persistent physical disability (to assess effects on disability-free survival). Analyses were performed according to a hierarchical testing plan. RESULTS: A total of 9971 participants were enrolled: 4984 were assigned to receive atorvastatin and 4987 to receive placebo. The mean (±SD) age of the participants was 74.7±4.5 years, and 51.9% were women. After a median of 5.9 years, a primary cardiovascular event had occurred in 297 participants (10.9 events per 1000 person-years) in the atorvastatin group and in 412 participants (15.5 events per 1000 person-years) in the placebo group (hazard ratio, 0.70; 95% confidence interval [CI], 0.61 to 0.82; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtorvastatinCardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsDisability EvaluationAgedAged, 80 and overFemaleHumansMaleDouble-Blind MethodKaplan-Meier EstimatePrimary PreventionPercutaneous Coronary InterventionAging in PlaceAustraliaGeneral PracticeDementiaFollow-Up StudiesTreatment Outcome

Substanzen

AtorvastatinHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Monash University Clinical Trials Centre, Faculty of Medicine, Nursing, and Health Sciences, Monash University, Melbourne, VIC, Australia.
  • Health of Older People, Bayside Health, Alfred Care Group, Melbourne, VIC, Australia.
  • Victorian Heart Institute, Monash University, Clayton, VIC, Australia.
  • Department of Neurology, Bayside Health, Alfred Care Group, Melbourne, VIC, Australia.
  • Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia.

ORCID-Profile: John J McNeil, Mark R Nelson

Förderung

  • National Heart Foundation of Australia
  • National Health and Medical Research Council
  • Faculty of Medicine, Nursing and Health Sciences, Monash University

Zitieren

APA

Zoungas, S., Wolfe, R., Moran, C., Nicholls, S. J., Cloud, G. C., Reid, C. M., Τonkin, A. M., Beilin, L., Wierzbicki, A. S., Chong, T. T., Broder, J. C., Curtis, A. J., Flanagan, Z., Hopper, I., Ryan, J., Spark, S., McNeil, J. J., Nelson, M. R., & STAREE Investigators (2026). Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. New England Journal of Medicine, 395(13), 1259-1272. https://doi.org/10.1056/nejmoa2607314

Vancouver

Zoungas S, Wolfe R, Moran C, Nicholls SJ, Cloud GC, Reid CM, et al. Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. New England Journal of Medicine. 2026;395(13):1259-1272. doi:10.1056/nejmoa2607314

BibTeX
@article{Zoungas2026,
  author = {Zoungas, Sophia and Wolfe, Rory and Moran, Chris and Nicholls, Stephen J and Cloud, Geoffrey C and Reid, Christopher M and Τonkin, Andrew M and Beilin, Lawrence and Wierzbicki, Anthony S and Chong, Trevor T-J and Broder, Jonathan C and Curtis, Andrea J and Flanagan, Zachary and Hopper, Ingrid and Ryan, Joanne and Spark, Simone and McNeil, John J and Nelson, Mark R and STAREE Investigators, STAREE Investigators},
  title = {Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {395},
  number = {13},
  pages = {1259--1272},
  doi = {10.1056/nejmoa2607314}
}
Kostenlos starten →